Clinical Trials Logo

Filter by:
NCT ID: NCT06340165 Recruiting - Breast Cancer Clinical Trials

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Start date: February 4, 2024
Phase:
Study type: Observational

This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and different molecular subtypes of breast cancer. Evidence-based medicine evidence for clinicians. Although the clinical application of amlotinib in breast cancer treatment is a supra-indication drug, in view of its high safety and possible good efficacy for advanced breast cancer, some patients have been clinically adopted to try the treatment after communicating with their families. This study provides evidence for the further use of amlotinib in breast cancer treatment by analysing the efficacy and safety of amlotinib in real-world applications.

NCT ID: NCT06340061 Active, not recruiting - Glaucoma Clinical Trials

The Aim of This Study is to Investigate the Correlation Between the Severity of Glaucoma and Corneal Biomechanics as Well as Anterior Chamber Parameters.

Start date: October 20, 2022
Phase:
Study type: Observational

The ocular biomechanical differences between the normal control group and primary glaucoma patients, including those treated with conventional medication, laser therapy, and surgery, were compared. Additionally, an investigation was conducted to explore the relationship between anterior chamber parameters, corneal biomechanics, and the severity of glaucoma

NCT ID: NCT06340048 Recruiting - Heart Failure Clinical Trials

Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure

Start date: September 5, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.

NCT ID: NCT06339775 Recruiting - Clinical trials for Acute B-cell Lymphoblastic Leukemia

Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

Start date: September 1, 2023
Phase: Phase 4
Study type: Interventional

B-ALL patients received regular follow-up after allogeneic hematopoietic stem cell transplantation, and in case of recurrence, they were given Blinatumomab. Anti-treatment was followed by DLI, and the second course was performed 1-2 months after DLI. Patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment. (MNC infusion is about 5×10^7/kg~1×10^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 (8 to 21 days in total), followed by DLI treatment (infusion of MNC approximately 5×10^7/kg~1×10^8/kg). Objective To observe and analyze the efficacy and side effects of Blinatumomab followed by donor lymphocyte infusion in patients with relapsed acute B lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation in our hospital.

NCT ID: NCT06339749 Recruiting - Preeclampsia Clinical Trials

Pregnancy Outcomes in Normotensive VS stage1 Hypertension

Start date: April 25, 2024
Phase:
Study type: Observational

In 2017, the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines built on evidence that elevated blood pressure increases cardiovascular mortality in the general population, Reclassification of BP; however, these diagnostic definitions do not include pregnant women, and whether newly diagnosed stage 1 hypertension affects pregnancy complications remains unclear. In this study, the combination of maternal factors, MAP and PLGF was used to comprehensively analyze the risk factors of preeclampsia through the "Bayesian rule" developed by the British Fetal Medicine Foundation (FMF). According to the guidelines and consensus, the pregnant women were considered to be at high risk when the calculated risk was higher than 1% of the population. To compare the pregnancy outcomes of women with normal blood pressure in the first trimester and stage 1 hypertension in different risk groups, and to find out whether screening for preeclampsia can be omitted for women with normal blood pressure in the first trimester, while screening for preeclampsia should still be performed for women with stage 1 hypertension as an independent moderate risk factor, and finally to optimize the screening strategy for preeclampsia.

NCT ID: NCT06339697 Completed - Colon Polyp Clinical Trials

Short-term Effects of Bowel Preparation on Gut Microbiome in Patients Undergoing Endoscopic Colon Polypectomy

Start date: December 1, 2022
Phase: Phase 4
Study type: Interventional

To investigate the role of different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate) on the composition, evolution and recovery of the gut microbiome of patients with colonic polyps undergoing bowel preparation.

NCT ID: NCT06339619 Recruiting - Clinical trials for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Start date: March 11, 2024
Phase: Phase 2
Study type: Interventional

The goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line standard treatment with PD-1 inhibitors in combination with chemotherapy.

NCT ID: NCT06339489 Not yet recruiting - Clinical trials for Bone Diseases, Metabolic

The Bone Metabolism Characteristics of Premature Ovarian Insufficiency

POI
Start date: April 1, 2024
Phase:
Study type: Observational

Explore the bone metabolism characteristics of premature ovarian insufficiency.

NCT ID: NCT06339385 Completed - Pain Clinical Trials

Management of PADIS in Emergency Intensive Care Unit

Start date: June 13, 2021
Phase:
Study type: Observational

Investigate the prevalence of PADIS in EICU, as well as the awareness and clinical implementation status of medical staff towards PADIS. The investigators conducted a multicenter cross-sectional survey in mainland China, including a one-day point prevalence investigation and a questionnaire survey. The inclusion criteria encompassed all adult patients admitted to the participating emergency department intensive care units (EDICUs) during the on-site screening, while exclusion criteria comprised patients aged less than 18 years, EDICU stays duration less than 24 hours before the screening, and participation in other concurrent trials. Hospital and nursing records from the 24 hours preceding enrollment were examined to document the assessment rate of pain, agitation-sedation, and delirium. Physicians and nurses on duty 24 hours before the patients' enrollment was invited to complete the questionnaire survey regarding the ICU profiles, professional expertise, assessment and treatment of PAD, early mobilization, and sleep improvement practices.

NCT ID: NCT06339307 Recruiting - Gastric Cancer Clinical Trials

A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients

Start date: February 15, 2024
Phase:
Study type: Observational

In our prior research, a risk scoring model for the occurrence of lymph node metastasis in patients who underwent radical gastrectomy for gastric cancer was established. To further validate this scoring model, a prospective study has been designed with the aim of prospectively assessing the model's clinical applicability.